Daily Brief Singapore: Pfizer Inc, Splunk Inc, Under Armour and more

In today’s briefing:

Pfizer Inc.: The Global Blood Therapeutics Acquisition & Other Drivers

While operating in a difficult foreign exchange environment, Pfizer maintained a good operational performance in the second quarter and delivered an all-around beat, exceeding Wall Street expectations on all counts.
The chance of a future variety that combines the severity of the original virus with the contagiousness of Omicron nevertheless persists.
Among major updates, Pfizer went on to acquire Global Blood Therapeutics to strengthen its commitment to sickle cell disease.

Splunk had a robust set of results with a top-line outperformance and it also exceeded the operating margin and earnings expectations for the quarter.
Positive consumer engagement was seen by the management with robust competitive win rates, good business momentum, and a high net retention rate.
In spite of the solid top and bottom line, the total ARR and cloud ARR came short of management expectations.

Under Armour’s brand strength helped the company deliver an all-around beat while navigating the present environment.
The company’s financial performance has been decent as its wholesale revenue increased while the eCommerce revenue and direct-to-consumer revenue decreased.
The company is planning to launch a new footwear platform, Kevin, that can change the landscape of athletic footwear.

💡 Before it’s here, it’s on Smartkarma

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network